Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $297.3 million.

  • Taysha Gene Therapies' Cash & Equivalents rose 8856.48% to $297.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.3 million, marking a year-over-year increase of 8856.48%. This contributed to the annual value of $139.0 million for FY2024, which is 340.7% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Cash & Equivalents stood at $297.3 million, which was up 8856.48% from $312.8 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Cash & Equivalents peaked at $312.8 million during Q2 2025, and registered a low of $36.9 million during Q3 2022.
  • Moreover, its 4-year median value for Cash & Equivalents was $124.0 million (2024), whereas its average is $135.3 million.
  • Over the last 5 years, Taysha Gene Therapies' Cash & Equivalents had its largest YoY gain of 34467.96% in 2023, and its largest YoY loss of 3610.67% in 2023.
  • Taysha Gene Therapies' Cash & Equivalents (Quarter) stood at $87.9 million in 2022, then soared by 63.79% to $143.9 million in 2023, then dropped by 3.41% to $139.0 million in 2024, then surged by 113.86% to $297.3 million in 2025.
  • Its Cash & Equivalents stands at $297.3 million for Q3 2025, versus $312.8 million for Q2 2025 and $116.6 million for Q1 2025.